ライフサイエンスコーパス: hypertonic saline

1 , dextran, gelatin, hydroxyethyl starch, and hypertonic saline).

2 dverse effects theoretically associated with hypertonic saline.

3 , but only one directly compared mannitol to hypertonic saline.

4 uced in rats by episcleral vein injection of hypertonic saline.

5 nse after an intraperitoneal injection of 1M hypertonic saline.

6 s that may be up-regulated with edema and/or hypertonic saline.

7 IOP produced by episcleral vein injection of hypertonic saline.

8 urface, which was significantly augmented by hypertonic saline.

9 intracranial disease should be treated with hypertonic saline.

10 eater than in wild-type mice pretreated with hypertonic saline.

11 This response was completely abrogated by hypertonic saline.

12 nt until recently were water restriction and hypertonic saline.

13 ot small bowel organ water was diminished by hypertonic saline.

14 teric pain challenge with an injection of 5% hypertonic saline.

15 exia is stimulated by chronic consumption of hypertonic saline.

16 tation (equal salt), and MV-HTN with 4 mL/kg hypertonic saline.

17 ithelial Na channels, and resuscitation with hypertonic saline.

18 S) and resuscitated with Ringer's lactate or hypertonic saline.

19 was seen with and without administration of hypertonic saline.

20 Continuous IV infusion 3% hypertonic saline.

21 es adopted the approach of giving a bolus of hypertonic saline.

22 ients treated with continuous IV infusion 3% hypertonic saline.

23 , 4 [3-6] to 7 [6-9]; p = 0.008) after 23.4% hypertonic saline.

24 of 0.9% saline or various concentrations of hypertonic saline.

25 ently with nebulized racemic epinephrine and hypertonic saline.

26 CH selected the nebulization technique using hypertonic saline.

27 with continuous intravenous infusion of 7.5% hypertonic saline (0.5 mL/hr; acetate/chloride, 50:50) a

28 us intravenous infusion of 0.9% saline or 3% hypertonic saline (1.5 mL/kg/hr) for 48 hr.

29 on-directed therapies (mannitol, 56% vs 21%; hypertonic saline, 14% vs 7%; hypothermia, 24% vs 10%; p

30 Clinically relevant concentrations of hypertonic saline (20 mM) significantly augmented CD69 e

31 greater increase measured using 23.4% or 30% hypertonic saline (23.4%, 365.0 +/- 8.8 mosm/L, p < .05

32 Group 2 (n = 15) received standard care and hypertonic saline (30%) via infusion to maintain serum s

33 out the 300-min period by all but the lowest hypertonic saline (4.2% NaCl).

34 e equisodium but different concentrations of hypertonic saline: 4.2%, 7.5%, 10%, 23.4%, and 30%.

35 normal saline; 2-TBI, normal saline; 3-TBI, hypertonic saline; 4-TBI, 100mM NaLac, 5-TBI, 500 mM NaL

36 y assigned to receive treatment with inhaled hypertonic saline (5 ml of 7 percent sodium chloride) fo

37 mOsm/L) as was water content of small bowel (hypertonic saline, 69.1+/-5.8%; normal saline, 74.7+/-0.

38 Animals were treated with hypertonic saline (7.5% NaCl, 4 mL/kg) before or after c

39 Hypertonic saline (7.5%) treatment significantly attenua

40 We hypothesized that hypertonic saline (7.5%) would reverse these detrimental

41 water content was significantly reduced with hypertonic saline (73.9+/-1.1%; 359+/-10 mOsm/L) (mean+/

42 (75.6 +/- 1.3%, 339 +/- 16 mOsm/L), and 7.5% hypertonic saline (74.9 +/- 0.7%, 360 +/- 23 mOsm/L) sig

43 nitol (74.4 +/- 1.2%, 352 +/- 15 mOsm/L), 5% hypertonic saline (75.6 +/- 1.3%, 339 +/- 16 mOsm/L), an

44 .8%; normal saline, 74.7+/-0.71%) and brain (hypertonic saline, 78.1+/-0.87%; normal saline, 79.2+/-0

45 sphere of wildtype mice was attenuated after hypertonic saline (79.9% +/- 0.5%; mean +/- SEM) but not

46 ine had no effect on the postischemic edema (hypertonic saline: 80.3% +/- 0.7%; 0.9% saline: 80.3% +/

47 ular action principle in mechanistic detail: Hypertonic saline acts via metalloproteinase 9 (MMP9).

48 After 60 mins, hypertonic saline administered at 50 mosm/kg resulted in

49 ined at least within high normal limits, but hypertonic saline administered to 145-155 mmol/L may be

50 The use of therapeutic interventions such as hypertonic saline administration and decompressive crani

51 easured over 4 h and again at 24 h following hypertonic saline administration.

52 ce remained only 50% regardless of timing of hypertonic saline administration.

53 e lung injury in wild-type mice treated with hypertonic saline after cecal ligation and puncture was

54 Osmotherapy with hypertonic saline ameliorates cerebral edema associated

55 nt isotonic and hypotonic challenges, and to hypertonic saline, an effective therapy for mucus hydrat

56 pression in the MnPN after administration of hypertonic saline and Ang-II in both spontaneously sleep

57 to compare the effects of equimolar doses of hypertonic saline and dextran solution (HSD, Rescueflow)

58 ere treated with different concentrations of hypertonic saline and endotoxin of Escherichia coli O111

59 ng advantageous resuscitative fluids such as hypertonic saline and hemoglobin-based oxygen carriers a

60 arch has demonstrated an association between hypertonic saline and hyperchloremia, limited data exist

61 ce secondary brain injury through the use of hypertonic saline and induced hypothermia.

62 Systemic administration of hypertonic saline and intracerebroventricular (i.c.v.) i

63 Both hypertonic saline and mannitol appear to lower intracran

64 Hypertonic saline and mannitol are used less in infants

65 d determined the effects of osmotherapy with hypertonic saline and mannitol on total lung water, as w

66 outcome was hospital billing for parenteral hypertonic saline and mannitol use, by day of service.

67 ation, and administrations schedule for both hypertonic saline and mannitol.

68 n Brown Norway rats (N = 26) by injection of hypertonic saline and monitored for 5 weeks.

69 rmonatremic controls; concurrent infusion of hypertonic saline and myoinositol increased brain myoino

70 ormonatremic animals, concurrent infusion of hypertonic saline and myoinositol increased brain myoino

71 mber of studies show the cellular effects of hypertonic saline and no studies, to our knowledge, have

72 fibrillary acidic protein immunostaining in hypertonic saline and normal saline treated rats, and un

73 The intervention arm prepared hypertonic saline and performed HSNIG.

74 nificantly improved in patients treated with hypertonic saline and placebo, whereas the residual volu

75 active treatment group (n = 158) received 7% hypertonic saline and the control group (n = 163) receiv

76 The MnPN also contains cells responsive to hypertonic saline and to angiotensin-II (Ang-II).

77 were randomized to control (with and without hypertonic saline) and mesenteric venous hypertension wi

78 s, chronic dehydration (produced by drinking hypertonic saline) and sustained hypovolemia (produced b

79 s: 4 followed a nebulization technique using hypertonic saline, and 2 followed a chest or abdomen mas

80 3% (2,069 of 6,238) of the patients received hypertonic saline, and 40% (2,500 of 6,238) received man

81 % with hypertonic saline/dextran, 75.7% with hypertonic saline, and 75.1% with normal saline (P = .88

82 addition, vogue methods such as hypothermia, hypertonic saline, and aggressive surgical decompression

83 compared the effectiveness of daily rhDNase, hypertonic saline, and alternate-day rhDNase in children

84 The role of colloids, hypertonic saline, and hemoglobin solutions in trauma re

85 GABAergic neurones in spontaneously sleeping hypertonic saline- and Ang-II-treated rats versus respec

86 y reactivity to NK A (NKA), substance P, and hypertonic saline; and to examine HIB before and after c

87 emic encephalopathy and early treatment with hypertonic saline are critical for successful outcomes.

88 studied whether these protective effects of hypertonic saline are related to improved gammadeltaT ce

89 We used perineurial injection of hypertonic saline as a tool to open the perineurial barr

90 lung water content were attenuated with 7.5% hypertonic saline at all time points.

91 Treatment with 7.5% hypertonic saline attenuated blood-brain barrier disrupt

92 ries of experiments (n = 32), treatment with hypertonic saline attenuated postischemic blood-brain ba

93 via the perivascular pool of aquaporin-4, 2) hypertonic saline attenuates blood-brain barrier disrupt

94 ical role in water egress from brain; and 3) hypertonic saline attenuates blood-brain barrier disrupt

95 We have previously shown that treatment with hypertonic saline attenuates cerebral edema associated w

96 tested the hypothesis that osmotherapy with hypertonic saline attenuates cerebral edema following ex

97 Inhaled hypertonic saline attenuates postshock acute lung injury

98 ly higher (88%) than in animals treated with hypertonic saline before cecal ligation and puncture (50

99 of human polymorphonuclear neutrophils with hypertonic saline before stimulation with formyl methion

100 23.4% hypertonic saline bolus administration.

101 rapy relies on inhaled deoxyribonuclease and hypertonic saline but does not address the elastolytic d

102 he novel pharmacologic agent dexanabinol; b) hypertonic saline; c) mild hypothermia; and d) decompres

103 These data indicate that hypertonic saline can modulate gammadeltaT cell function

104 Hypertonic saline causes increased hydraulic conductivit

105 to 116 traits assessed through blood tests, hypertonic saline challenge tests, questionnaires, and s

106 injury was attenuated by both amiloride and hypertonic saline, combined administration of amiloride

107 ars with cystic fibrosis, the use of inhaled hypertonic saline compared with isotonic saline did not

108 At equiosmotic doses of hypertonic saline, concentration plays no substantial ro

109 nd ventricular volumes increased after 23.4% hypertonic saline, consistent with a reduction in brain

110 We investigated the hypothesis that bolus hypertonic saline decreases cerebral edema in severe hep

111 Hypertonic saline decreases intestinal edema and improve

112 being brought into clinical use, especially hypertonic saline dextran, haemoglobin-based oxygen carr

113 ons of patients with severe TBI (GOSE </=4) (hypertonic saline/dextran vs normal saline: 53.7% vs 51.

114 e 250-mL bolus of 7.5% saline/6% dextran 70 (hypertonic saline/dextran), 7.5% saline (hypertonic sali

115 Survival at 28 days was 74.3% with hypertonic saline/dextran, 75.7% with hypertonic saline,

116 suscitation with either hypertonic saline or hypertonic saline/dextran, compared with normal saline,

117 oinositol or infusion of myoinositol without hypertonic saline did not increase brain myoinositol lev

118 Hypertonic saline did not reduce nerve density, but did

119 5.0 +/- 8.8 mosm/L, p < .05 vs. other lesser hypertonic saline doses).

120 of intracerebral hematoma, a single dose of hypertonic saline effectively reduces the intraparenchym

121 Inhaled hypertonic saline enhances mucociliary clearance, improv

122 Our findings suggest that hypertonic saline enhances the elimination of inflammato

123 had elevated IOP induced in the left eye by hypertonic saline episcleral vein injections.

124 Hypertonic saline-evoked synaptic vesicle fusion is simi

125 se data demonstrate that 1) osmotherapy with hypertonic saline exerts antiedema effects via the periv

126 We tested the hypothesis that hypertonic saline exerts its antiedema effect by promoti

127 The effect of timing of hypertonic saline exposure on A3 receptor expression and

128 ne, combined administration of amiloride and hypertonic saline failed to further protect the gut.

129 ock (shock) or traumatic brain injury (TBI), hypertonic saline failed to improve survival.

130 Hypertonic saline fluids used to resuscitate trauma pati

131 normal saline, 3% hypertonic saline, or 7.5% hypertonic saline for 24, 48, 72, and 96 hrs.

132 We hypothesized that aerosolized inhaled hypertonic saline given at the onset of resuscitation wi

133 Hypertonic saline given to children with bronchiolitis i

134 Hypertonic saline, given as intermittent boluses, has jo

135 On average, LCI decreased in the hypertonic saline group (n = 12) by 1.19 z-scores units

136 re enrolled and randomly assigned, 76 to the hypertonic saline group and 74 to the isotonic saline gr

137 Six participants in the hypertonic saline group had ten serious adverse events a

138 eported were cough (two patients [3%] in the hypertonic saline group vs three [4%] in the isotonic sa

139 ed in an increase in serum osmolarity in all hypertonic saline groups (p < .05 vs. normal saline), wi

140 In contrast in alpha-Syn(-/-) mice, hypertonic saline had no effect on the postischemic edem

141 Hypertonic saline has been shown to be an effective osmo

142 Hypertonic saline has been shown to modulate cell shape

143 shown promise in poor grade patients, while hypertonic saline has shown better intracranial pressure

144 have shown a potential benefit of nebulized hypertonic saline; however, its effect in the emergency

145 irway dehydration could be reversed, we used hypertonic saline (HS) as an osmolyte to rehydrate ASL.

146 Pretreatment with hypertonic saline (HS) can prevent these changes.

147 , and efficacy of preventive inhalation with hypertonic saline (HS) compared with isotonic saline (IS

148 urrent evidence is unclear about the role of hypertonic saline (HS) for the acute treatment of bronch

149 Two previous meta-analyses of nebulized hypertonic saline (HS) on hospital length of stay (LOS)

150 n, have found a limited benefit of nebulized hypertonic saline (HS) treatment in the pediatric emerge

151 produced by a rehydrating treatment based on hypertonic saline (HS), a current CF clinical treatment.

152 An alternative mucolytic therapy is hypertonic saline (HS); however, HS may potentiate neutr

153 efore and after intramuscular injection with hypertonic saline (HS, 5%, 100 microl).

154 Hypertonic saline (HS, i.v. bolus), which produced a phy

155 atients received 4 mL of 3% sodium chloride (hypertonic saline [HS group]) or 0.9% sodium chloride (n

156 Hypertonic saline (HTS) is an accepted treatment for tra

157 Inhaled hypertonic saline (HTS) treatment is used to improve lun

158 ysiologic differences in neural responses to hypertonic saline (HTS) were investigated in subjects wi

159 randomized to receive either 7.2% saline/6% hypertonic saline hydroxyethyl starch (4 mL/kg) or vehic

160 y resuscitation, which was not influenced by hypertonic saline hydroxyethyl starch administration.

161 ing results in other models of brain injury, hypertonic saline hydroxyethyl starch failed to improve

162 This might explain why hypertonic saline hydroxyethyl starch has failed to impr

163 ocampal CA1 and neocortex with no effects of hypertonic saline hydroxyethyl starch on neuronal surviv

164 Hypertonic saline hydroxyethyl starch treatment resulted

165 Three percent hypertonic saline (HYS) has been suggested as a means of

166 In addition, hypertonic saline improved intestinal transit, possibly

167 Inhaled hypertonic saline improved the LCI(2.5) in children aged

168 Bolus 23.4% hypertonic saline improves surveillance neuromonitoring

169 er A3 receptors may diminish the efficacy of hypertonic saline in a mouse model of acute lung injury.

170 , and show potentially beneficial effects of hypertonic saline in acute cervical SCI.

171 The Efficacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis (GUERANDE

172 to account for the effects of amiloride and hypertonic saline in CF lung disease, indicating the nee

173 a indicate the clinical benefit of nebulized hypertonic saline in cystic fibrosis lung disease, with

174 Early and continuous infusion of hypertonic saline in patients with severe cerebrovascula

175 In addition, hypertonic saline-induced Fos-ir was colocalized with th

176 e, this study focused on the hypothesis that hypertonic saline-induced improvements in histological o

177 tasis cohort, spontaneously expectorated and hypertonic saline-induced sputa were collected, and mucu

178 ing a sustained experimental pain challenge (hypertonic saline infused in the masseter muscle) with a

179 50 patients with hyponatremia who underwent hypertonic saline infusion.

180 Hyper-osmolality induced via 2% hypertonic saline ingestion significantly decreased, whe

181 Hypertonic saline inhalation acutely reduced non-cystic

182 ratio of Mean Expiratory Flow after 240s of hypertonic saline inhalation with respect to the age- an

183 (Forced Expiratory Flow Volume after 240s of hypertonic saline inhalation; p = 4.81*10(-4)) and CD14

184 Additionally, nebulized hypertonic saline inhibited matrix -metalloproteinase-13

185 Unilateral elevation of IOP was produced by hypertonic saline injection into an episcleral vein in 2

186 s were tracked across painful (intramuscular hypertonic saline injection) and non-painful (baseline,

187 ncreased saline intake after dehydration and hypertonic saline injection.

188 eurons were activated by fluid satiation and hypertonic saline injection.

189 mor outflow with laser coagulation or limbal hypertonic saline injection.

190 IOP elevation was induced in rats by hypertonic saline injections into episcleral veins.

191 l IOP elevation was produced by injection of hypertonic saline into the episcleral veins.

192 was raised in Brown Norway rats by injecting hypertonic saline into the limbal venous system.

193 was raised in brown Norway rats by injecting hypertonic saline into the limbal venous system.

194 weeks following these injections we injected hypertonic saline intraperitoneally into the rat.

195 1.0%; contralateral, 79.7 +/- 0.6%) and 7.5% hypertonic saline (ipsilateral, 82.3 +/- 1.3%; contralat

196 Treatment with 5% hypertonic saline (ipsilateral, 83.8 +/- 1.0%; contralat

197 Hypertonic saline is currently being used in the treatme

198 Hypertonic saline is effective in reducing organ water c

199 Evidence for other treatments such as hypertonic saline is evolving but not clearly defined ye

200 We found that hypertonic saline is more effective than mannitol for th

201 Inhaled hypertonic saline is recommended as therapy for patients

202 Hypertonic saline is used predominantly, yet there remai

203 One of these treatments, hypertonic saline, is already in use, whereas others are

204 miloride suppresses the beneficial effect of hypertonic saline, it has been previously concluded that

205 Nine reported that hypertonic saline lowered intracranial pressure and two

206 miloride and small-volume resuscitation with hypertonic saline may be a strategy worthy of further ev

207 igible trials, but our findings suggest that hypertonic saline may be superior to the current standar

208 in water content with continuous infusion of hypertonic saline may have therapeutic implication in th

209 Through osmotic forces, hypertonic saline may increase the volume of airway surf

210 en patients with 18 administrations of 23.4% hypertonic saline met inclusion criteria.

211 Hypertonic saline mitigates intestinal edema development

212 20), 5% hypertonic saline (n = 20), or 7.5% hypertonic saline (n = 18) as a chloride/acetate mixture

213 (n = 21), 20% mannitol (2 g/Kg) (n = 20), 5% hypertonic saline (n = 20), or 7.5% hypertonic saline (n

214 uced in rats by episcleral vein injection of hypertonic saline (N = 30).

215 non-blinded, randomised controlled trial of hypertonic saline nasal irrigation and gargling (HSNIG)

216 Although the anti-edema effects of hypertonic saline on brain are well documented in a vari

217 the effects of different tonicity of infused hypertonic saline on cerebral, lung, and small bowel wat

218 our findings and to evaluate the effects of hypertonic saline on functional outcomes.

219 We also assessed the effect of hypertonic saline on intraparenchymal pressure in differ

220 The beneficial effects of hypertonic saline on neuronal survival and on cerebral b

221 We aimed to assess the effect of inhaled hypertonic saline on the lung clearance index (LCI(2.5))

222 However, the effect of hypertonic saline on the macrophage remains unknown.

223 onfirmed enrolment eligibility to inhaled 7% hypertonic saline or 0.9% isotonic saline nebulised twic

224 ed in a blinded randomized fashion with 7.5% hypertonic saline or 0.9% normal saline in a 8-mL/kg int

225 34), alpha-Syn(-/-) mice treated with either hypertonic saline or 0.9% saline had smaller infarct vol

226 Hypertonic saline or co-loaded cargo was found to preven

227 Treating acidic ASL with hypertonic saline or heparin largely reversed the increa

228 mic shock, initial resuscitation with either hypertonic saline or hypertonic saline/dextran, compared

229 Of the 1,854 patients who received hypertonic saline or mannitol for >/= 2 days in the firs

230 yet there remains disagreement about whether hypertonic saline or mannitol is more effective.

231 Hypertonic saline or mannitol resuscitation, therefore,

232 uous infusion only for 48 hrs of either 7.5% hypertonic saline or normal saline (1 mL/kg/hr) (n=10 ea

233 uous intravenous infusion (1 mL/kg/hr) of 5% hypertonic saline or normal saline, respectively (n=10 e

234 umin) or crystalloids (n = 1443; isotonic or hypertonic saline or Ringer lactate solution) for all fl

235 ore fluid in response to either subcutaneous hypertonic saline or water deprivation with partial rehy

236 70 (hypertonic saline/dextran), 7.5% saline (hypertonic saline), or 0.9% saline (normal saline) initi

237 us intravenous infusion of normal saline, 3% hypertonic saline, or 7.5% hypertonic saline for 24, 48,

238 s over whether use of nebulized epinephrine, hypertonic saline, or bronchodilators should be routinel

239 Inhaled hypertonic saline osmotically draws water onto airway su

240 e interval, -1.6 to 5.7), with both favoring hypertonic saline over mannitol.

241 t concentrations of the same osmotic load of hypertonic saline over time.

242 mL vs. 3342 +/- 859 pg/mL, shock vs. shock + hypertonic saline, p = .006).

243 luid vs. 230 +/- 19 pg/mL, shock vs. shock + hypertonic saline, p = .009) and pretreatment with a mat

244 Hypertonic saline prevented intestinal tissue edema.

245 patients with cystic fibrosis, inhalation of hypertonic saline produced a sustained acceleration of m

246 Additionally, hypertonic saline reduced both neutrophil CD11b expressi

247 Nebulized hypertonic saline reduced inflammation (cytokine-induced

248 Both amiloride and hypertonic saline reduced T/HS-induced pulmonary permeab

249 Delayed treatment of hypertonic saline resulted in the greatest reduction in

250 S + VH + VEH) or 80 mL/kg normal saline with hypertonic saline (RESUS + VH + HTS).

251 A3 antagonists could improve the efficacy of hypertonic saline resuscitation by reducing side effects

252 l A3 receptors expression determines whether hypertonic saline resuscitation inhibits or aggravates p

253 Hypertonic saline resuscitation may therefore protect ho

254 Hypertonic saline resuscitation reduces tissue damage by

255 he effect of A3 receptors on the efficacy of hypertonic saline resuscitation was assessed in A3 recep

256 Hypertonic saline significantly lessened the effect of e

257 emorrhagic shock and multiple-system trauma, hypertonic saline solutions are increasingly being used

258 Randomized trials have suggested that hypertonic saline solutions may be superior to mannitol

259 n (LHSS) reward if rats are denied access to hypertonic saline solutions.

260 one either by a water deprivation test or by hypertonic saline stimulation together with copeptin (or

261 Highly concentrated hypertonic saline such as 23.4% provides a small volume

262 ed concentrations of menthol, capsaicin, and hypertonic saline that evoked comparable levels of nocif

263 postocclusion) was robustly attenuated with hypertonic saline therapy (ipsilateral, 81.59 +/- 0.52%;

264 cardiopulmonary resuscitation: 1) continuous hypertonic saline therapy maintained to achieve serum os

265 tischemic complication can be manipulated by hypertonic saline therapy.

266 ived unilateral episcleral vein injection of hypertonic saline to elevate IOP.

267 Intraperitoneal administration of hypertonic saline to the rat supraoptic nucleus (SON) in

268 For hypertonic saline-treated patients, mechanical ventilati

269 on was not different between 0.9% saline and hypertonic saline-treated wild-type mice.

270 Effects of the timing of hypertonic saline treatment administration on tissue los

271 de values should be monitored closely during hypertonic saline treatment as moderate elevations may i

272 brain water is responsive to continuous 7.5% hypertonic saline treatment begun at 24 hrs postischemia

273 c arrest/cardiopulmonary resuscitation, 7.5% hypertonic saline treatment did not attenuate water cont

274 f water content of extracerebral organs with hypertonic saline treatment may have therapeutic implica

275 Results show that hypertonic saline treatment reduced tissue loss that cor

276 rphonuclear neutrophils are activated before hypertonic saline treatment.

277 ceptor expression and degranulation, whereas hypertonic saline-treatment after formyl methionyl-leucy

278 This aggravating effect of delayed hypertonic saline-treatment was absent in A3 receptor kn

279 ly, mortality in wild-type mice with delayed hypertonic saline-treatment was significantly higher (88

280 comes Consortium multicenter out-of-hospital Hypertonic Saline Trial in patients with Glasgow Coma Sc

281 Hypertonic saline triggers polymorphonuclear neutrophils

282 ating that there is a therapeutic window for hypertonic saline use after traumatic brain injury.

283 Hypertonic saline use increased and mannitol use decreas

284 %; difference, 2.2% [95% CI, -4.5% to 9.0%]; hypertonic saline vs normal saline: 54.3% vs 51.5%; diff

285 urther increased to 31.8 +/- 3.1% when 20 mM hypertonic saline was added with lipopolysaccharide.

286 At 48 weeks, treatment with hypertonic saline was associated with a significant decr

287 In the study group, nebulized hypertonic saline was delivered at the end of the shock

288 The efficacy of hypertonic saline was equivalent to furosemide (ipsilate

289 Hypertonic saline was instituted as chloride/acetate mix

290 to 1510) and that between daily rhDNase and hypertonic saline was pound1409 (440 to 2318).

291 Volumes before and after 23.4% hypertonic saline were compared with Wilcoxon signed ran

292 this study, we tested the hypothesis that a) hypertonic saline when given as an intravenous bolus and

293 , and brain water content is attenuated with hypertonic saline when serum osmolality is >350 mOsm/L w

294 amage was induced by episcleral injection of hypertonic saline, which caused sclerosis and blockade o

295 ence interval, 1.6 to 11.7; P=0.02), whereas hypertonic saline with amiloride did not improve FEV1 (m

296 mal rats respond to intravenous infusions of hypertonic saline with gradual, linear increases in disc

297 Furthermore, inhalation of hypertonic saline with placebo improved the forced expir

298 ing treatment with continuous IV infusion 3% hypertonic saline, with moderate hyperchloremia independ

299 onatremic and hyponatremic rats, infusion of hypertonic saline without myoinositol or infusion of myo

300 Long-term inhalation of hypertonic saline without pretreatment with amiloride (i